Hyperion DeFi (NASDAQ:HYPD) and CNBX Pharmaceuticals (OTCMKTS:CNBX) operate in the medical sector but exhibit markedly different financial characteristics and market positioning. A comprehensive comparison across multiple investment metrics reveals that CNBX Pharmaceuticals outperforms on six of eleven measured factors, though both companies face profitability challenges.
Hyperion DeFi generated $810,000 in gross revenue with a price-to-sales ratio of 56.67, but reported a net loss of $45.31 million and negative earnings per share of $11.80. The company maintains a price-to-earnings ratio of negative 0.34. CNBX Pharmaceuticals, by contrast, reports no available revenue data, earnings data, or profitability metrics, reflecting its status as a clinical-stage enterprise with no commercialized products generating income.
Profitability metrics underscore the early-stage nature of both ventures. Hyperion DeFi shows a negative return on equity of 129.97% and negative return on assets of 92.39%. CNBX Pharmaceuticals provides no comparable profitability figures, suggesting insufficient operational history to calculate these measures.
Institutional and insider ownership structures diverge significantly. Hyperion DeFi holds 25.8% institutional ownership and 10.9% insider ownership. CNBX Pharmaceuticals shows considerably higher concentrations, with 98.2% institutional ownership and 73.5% insider ownership. Elevated institutional participation is typically viewed as a bullish signal, indicating confidence among large money managers and hedge funds regarding long-term performance prospects.
Analyst coverage presents another point of distinction. Hyperion DeFi has received four analyst ratings: two sell recommendations, one buy rating, and one strong buy rating, yielding a composite rating score of 2.25. Analysts assign a consensus target price of $5.88, suggesting potential upside of 45.78%. CNBX Pharmaceuticals has received no analyst ratings or price targets, reflecting limited Wall Street attention.
Hyperion DeFi develops ophthalmic therapeutics using a proprietary microdose array print platform. Its pipeline includes MicroPine for pediatric myopia progression, MicroLine for presbyopia, and Mydcombi for pharmaceutical mydriasis—all in Phase III clinical development. The company operates under license agreements with Bausch Health Ireland Limited, Arctic Vision (Hong Kong) Limited, and Senju Pharmaceutical Co., Ltd.
CNBX Pharmaceuticals focuses on cannabinoid-based cancer treatments. Its lead candidate, Cannabics SR, is an oral capsule targeting advanced cancer and cancer anorexia cachexia syndrome. The company is developing additional candidates including PLP-33 for colorectal polyps, BRST-33 for breast cancer, MLN-33 for melanoma, PRST-33 for prostate cancer, and RCC-33 for colorectal cancer, alongside a diagnostic tool called Cannabics CDx.
